NVO files an NDA with the FDA for once-weekly CagriSema, a combo obesity injection showing superior weight loss in obese patients in phase III studies.

The perception of GLP-1s — and the people who use them — is getting better, but work still must be done to avoid stigma.

Novo Nordisk filed an FDA application for weekly CagriSema after trials showed up to 22.7% weight loss versus placebo.

Topline data from the phase 3 ATTAIN-MAINTAIN trial evaluated orforglipron for weight maintenance after initial treatment with Wegovy or Zepbound in adults with obesity or overweight.

Danish pharma major Novo Nordisk has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for once-weekly CagriSema (cagrilintide and semaglutide) injection, to be used ...

Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection ...

Research indicates low-carb diets may enhance appetite regulation and reduce food cues in women with lipedema, offering a ...

The telehealth service now provides a digital weight management programme featuring genuine prescription GLP-1 agonist drugs.

The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market.

A recent study from the University of Cape Town reveals a concerning double burden of malnutrition among young children in ...

The Partnership to Fight Chronic Disease analysis shows 5% of people account for nearly half of healthcare spending, with ...

HONG KONG SAR - Media OutReach Newswire - 19 December 2025 - Amid a global surge in demand for the weight-management ingredient GLP-1, the Hong Kong market has ...